Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Ascending-dose, Randomized, Placebo-controlled, Parallel, Double-blind, Single-dose, First-in-Human Study to Evaluate the Safety and Pharmacokinetics of RECCE327 in Healthy Male Subjects

Next Previous
Search
Trial Profile

An Ascending-dose, Randomized, Placebo-controlled, Parallel, Double-blind, Single-dose, First-in-Human Study to Evaluate the Safety and Pharmacokinetics of RECCE327 in Healthy Male Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RECCE 327 (Primary) ; Cetirizine
  • Indications Bacterial infections; Burn infections; Clostridium infections; COVID 2019 infections; Escherichia coli infections; Sepsis; Streptococcal infections
  • Focus Adverse reactions; First in man
  • Sponsors Recce Pharmaceuticals

    • Most Recent Events

    • 29 Mar 2024 Results (N-80) assessing safety, pharmacokinetics and pharmacodynamics of IV R327, presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 13 Mar 2024 According to a Recce Pharmaceuticals media release, the company will present data from this study at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.
    • 20 Jul 2023 According to a Recce Pharmaceuticals media release, the company will provide interim proof-of-efficacy data in pre-sepsis patients in H2 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top